{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:48:49Z","timestamp":1761864529114},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,12,15]]},"DOI":"10.2169\/internalmedicine.1593-23","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T04:34:55Z","timestamp":1683693295000},"page":"3619-3624","source":"Crossref","is-referenced-by-count":6,"title":["Primary Retroperitoneal Mucinous Cystadenocarcinoma during Long-term Administration of Infliximab for the Treatment of Crohn's Disease"],"prefix":"10.2169","volume":"62","author":[{"given":"Yoshiki","family":"Morihisa","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Urai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Iwagami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Ogino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Terashita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Morimura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Akamatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Uenoyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitaka","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117: 244-279, 2008.","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 13: 1299-1307, 2007.","DOI":"10.1002\/ibd.20211"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285, 2006.","DOI":"10.1001\/jama.295.19.2275"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Muller M, D&apos;Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. J Crohns Colitis 15: 840-859, 2021.","DOI":"10.1093\/ecco-jcc\/jjaa186"},{"key":"5","unstructured":"5. Motoyama T, Chida T, Fujiwara T, Watanabe H. Mucinous cystic tumor of the retroperitoneum. A report of two cases. Acta Cytol 38: 261-266, 1994."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Thamboo TP, Sim R, Tan SY, Yap WM. Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. J Clin Pathol 59: 655-657, 2006.","DOI":"10.1136\/jcp.2005.030122"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Green JM, Bruner BC, Tang WW, Orihuela E. Retroperitoneal mucinous cystadenocarcinoma in a man: case report and review of the literature. Urol Oncol 25: 53-55, 2007.","DOI":"10.1016\/j.urolonc.2006.02.015"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hrora A, Reggoug S, Jallal H, et al. Primary retroperitoneal mucinous cystadenocarcinoma in a male patient: a case report. Cases J 2: 7196, 2009.","DOI":"10.4076\/1757-1626-2-7196"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Shiau JP, Wu CT, Chin CC, Chuang CK. Long-term survival after hand-assisted laparoscopic approach of primary retroperitoneal mucinous cystadenocarcinoma in male: case report and review of literature. Eur Surg 45: 106-109, 2013.","DOI":"10.1007\/s10353-012-0184-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11. Vargas AC, Lam V, P&apos;ng CH. A rare case of primary retroperitoneal mucinous neoplasm in a male patient. Pathology 47: 384-386, 2015.","DOI":"10.1097\/PAT.0000000000000261"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12. Khurana A, Mukherjee U, Singaravel S. Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. Indian J Pathol Microbiol 59: 229-231, 2016.","DOI":"10.4103\/0377-4929.182022"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13. Myriokefalitaki E, Luqman I, Potdar N, Brown L, Steward W, Moss EL. Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis. Arch Gynecol Obstet 293: 709-720, 2016.","DOI":"10.1007\/s00404-015-3975-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14. Fujii S, Konishi I, Okamura H, Mori T. Mucinous cystadenocarcinoma of the retroperitoneum: a light and electron microscopic study. Gynecol Oncol 24: 103-112, 1986.","DOI":"10.1016\/0090-8258(86)90013-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15. Pearl ML, Valea F, Chumas J, Chalas E. Primary retroperitoneal mucinous cystadenocarcinoma of low malignant potential: a case report and literature review. Gynecol Oncol 61: 150-152, 1996.","DOI":"10.1006\/gyno.1996.0115"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16. Tomisaki I, Matsuyama A, Jotatsu M, Yamamura S, Onishi R, Fujimoto N. Primary retroperitoneal mucinous cystadenocarcinoma with transition from the mesothelium. IJU Case Rep 3: 137-140, 2020.","DOI":"10.1002\/iju5.12169"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Mazza-Stalder J, Nicod L, Janssens JP. [Extrapulmonary tuberculosis]. Rev Mal Respir 29: 566-578, 2012 (in French).","DOI":"10.1016\/j.rmr.2011.05.021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Papadopoulou E, Rampiadou C, Petsatodis E, Chloros D, Boutou A. Multiple extrapulmonary tuberculous abscesses developed postpartum in a non-HIV patient under anti-tuberculosis chemotherapy. Cureus 14: e21395, 2022.","DOI":"10.7759\/cureus.21395"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19. Hozaka Y, Mataki Y, Kurahara H, et al. Usefulness of <sup>18<\/sup>F-fluorodeoxyglucose-positron emission tomography\/computed tomography in primary cystadenocarcinoma of the mesentery: a case report. Surg Case Rep 6: 306, 2020.","DOI":"10.1186\/s40792-020-01079-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20. Dong A, Zhai Z, Wang Y, Zuo C. MRI, enhanced CT, and FDG PET\/CT in primary retroperitoneal mucinous cystadenocarcinoma. Clin Nucl Med 40: 50-53, 2015.","DOI":"10.1097\/RLU.0000000000000343"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21. Kamiyama H, Shimazu A, Makino Y, et al. Report of a case: Retroperitoneal mucinous cystadenocarcinoma with rapid progression. Int J Surg Case Rep 10: 228-231, 2015.","DOI":"10.1016\/j.ijscr.2015.04.004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22. Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn&apos;s disease: more than 13 years of real-world experience. Inflamm Bowel Dis 24: 490-501, 2018.","DOI":"10.1093\/ibd\/izx072"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23. Dulic S, Vasarhelyi Z, Bajnok A, et al. The impact of anti-TNF therapy on CD4+ and CD8+ cell subsets in ankylosing spondylitis. Pathobiology 85: 201-210, 2018.","DOI":"10.1159\/000484250"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24. Patel R, Lara S, Johnson J, Kulkarni P. New pancreatic adenocarcinoma in a Crohn&apos;s patient treated with tumor necrosis factor (TNF) inhibitors for 6 months. J Gastrointest Cancer 45: 226-229, 2014.","DOI":"10.1007\/s12029-014-9640-9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25. Xiao L, Sun L, Zhao K, Pan YS. Crohn&apos;s disease with infliximab treatment complicated by rapidly progressing colorectal cancer: a case report. World J Gastrointest Oncol 13: 305-311, 2021.","DOI":"10.4251\/wjgo.v13.i4.305"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26. M\u00fcller-Hermelink N, Braum\u00fcller H, Pichler B, et al. TNFR1 signaling and IFN-\u03b3 signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13: 507-518, 2008.","DOI":"10.1016\/j.ccr.2008.04.001"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas ML, Gritzapis AD, Papamichail M. Compromised anti-tumor responses in tumor necrosis factor-\u03b1 knockout mice. Eur J Immunol 30: 1957-1966, 2000.","DOI":"10.1002\/1521-4141(200007)30:7<1957::AID-IMMU1957>3.0.CO;2-7"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 9: 361-371, 2009.","DOI":"10.1038\/nrc2628"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/24\/62_1593-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T03:18:59Z","timestamp":1702696739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/24\/62_1593-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":27,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1593-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"article-number":"1593-23"}}